Re:Cognition Health is enrolling volunteers to participate in studies.
The Aspect Study
In this study, researchers want to find out if an investigational drug called AVP-786 is safe and effective (useful) in managing agitation in adults with Alzheimer’s dementia, when compared to a placebo. To be eligible for this study, a potential participant must:
- Be between the ages of 50 and 90
- Have a diagnosis of probable Alzheimer’s disease
- Have moderate-to-severe agitation that interferes with daily life
The CVL-871-2001 Study
Do you, or someone you care for, have dementia? Have you/they lost interest in everyday life?
The CVL-871-2001 Study is looking at how safe an investigational medication is in people with dementia-related apathy and how it may work in the body. Apathy is a loss of interest in everyday life and lack of motivation. It is often a forgotten symptom of dementia. You, or someone you care for, may be able to take part if you/they:
- Are 50–85 years of age
- Have been diagnosed with dementia
- Have dementia-related apathy
You can learn more about the CVL-871-2001 Study at the following link: CVL-871 – Cerevel Therapeutics
The SIGNAL – AD Study
SIGNAL-AD is a clinical study of an investigational drug called Pepinemab. The study will evaluate the drug’s safety profile, brain imaging effects and potential effects on cognition in people with early Alzheimer’s disease (AD). Study assessments, testing and medication are provided at no cost to participants. Some people may receive stipends for participation.
- Are 55 to 85 years old Have evidence of Mild Cognitive Impairment
- Probable AD or mild-AD.
- Have a partner who will support you and participate in the study
TRAILRUNNER – ALZ 1
The TRAILRUNNER-ALZ 1 is a clinical research study for people with symptoms of the early stages of Alzherimer’s disease.
You may be able to join the TRAILRUNNER-ALZ 1 study if you:
- Are aged 60 to 85 years old
- Have memory loss that has gotten worse over time
- Have a trusted study partner
- A study partner is a person who knows you well and would notice any changes in your memory, thinking, mood and behavior. This could be your spouse, partner, friend, family member or someone whose job it is to help you. Your study partner would also consent to the research study.
The study is from Eli Lilly and Company
If you or a loved one has been diagnosed with Alzheimer’s disease, or a physician suspects it may be Alzheimer’s disease, you or they may be eligible to participate in a clinical research study. RethinkALZ is a new clinical trial for Alzheimer’s disease. The purpose of this trial is to determine if a new, twice-a day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer’s disease. Simufilam is an investigational drug candidate that has not been approved by the United States Food and Drug Association (FDA), or any regulatory agency, for the treatment of any condition.
To be considered for the RethinkALZ study, patients must:
- Be ages 50 to 87 years old
- Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease
- Have a gradual change in memory for six months or more
- Have a family member or loved one who can be available as a study partner during the entire study
- Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection
Other criteria will apply. There is no cost to the patient to participate in the RethinkALZ trial or for any of the study-related procedures. No hospitalization is required. You may be compensated for your time and travel for each clinical study appointment.
Aphelia is a pre-screener study that will use demographic information such as sex, age, race and ethnicity, medical history, memory assessments, and a blood draw to help identify people who may have markers, or biological signs of Alzheimer’s disease.
Why are Pre-Screener Tests Needed?
Alzheimer’s clinical trials can be complex and time consuming for participants who spend weeks screening for trials, only to learn they don’t meet criteria to participate. Pre-screeners seek to identify research-ready participants who will successfully enroll into appropriate clinical trials, saving valuable time and effort. To make these decisions, Aphelia will use demographic information such as sex, age, medical history, memory assessments, as well as laboratory results from a blood draw.
The Aphelia study will require one (1) visit to the research center and one (1) follow-up phone call. No experimental treatments are a part of this study.
This study is seeking 3,000 volunteers of all races, ethnicities, and backgrounds who:
- Are 50 to 90 years old
- Are experiencing trouble with their memory
- Have someone who can participate with them as a study partner